Pharmacovigilance Learning Pathway

Seriousness vs Severity in Pharmacovigilance: A Simple Guide with Examples Introduction: Why Seriousness and Severity Are Often Confused In general, while learning pharmacovigilance, many beginners find seriousness and severity confusing. When we hear the word serious , we naturally think the condition must be severe . Similarly, when an adverse event is described as severe , it often feels like it should automatically be considered serious . Because of this overlap in everyday language, these two terms are frequently misunderstood. However, in pharmacovigilance, seriousness and severity are distinct concepts and  not interchangeable . Seriousness is mainly related to regulatory requirements and reporting obligations . It focuses on the outcome of the adverse event and determines whether the case requires expedited reporting to regulatory authorities or inclusion in aggregate reports . When an event meets seriousness criteria, it must be reported within defined timelines....

My Pharmacovigilance Portfolio – Simulated ICSR Practice As part of my learning journey in Pharmacovigilance, I created a dedicated portfolio to capture my hands-on practice using simulated ICSR case summaries . The portfolio includes SIM-001 to SIM-020 , covering non-serious, serious, and special-situation cases, with a focus on: Seriousness assessment Narrative writing Follow-up query drafting ICSR case summary documentation 🔗 View my complete Pharmacovigilance Portfolio here: 👉 Portfolio This portfolio reflects my  ongoing learning as a Pharmacovigilance fresher and my preparedness for entry-level Drug Safety/Pharmacovigilance roles . 📩 Resume available on request. Please connect with me via Email or LinkedIn.

Medically Significant Events in Pharmacovigilance (PV) Medically significant events in pharmacovigilance are one of the seriousness criteria . Sometimes an adverse event may look minor or non-serious initially , but with time or long-term exposure, it can become severe and may lead to hospitalization or other serious outcomes . These events can act as early safety signals and often need urgent medical treatment . So, in PV, even if a case does not meet common seriousness criteria, such as hospitalization, it can still be classified as serious based on medical significance .

Practicing Narrative Writing in Pharmacovigilance (PV): Learner Notes with Simulated ICSR Examples Introduction While learning pharmacovigilance, I realized that understanding the guidelines and standard structure of narrative writing alone is not enough to feel confident in real-world PV case processing. Narrative writing started to make more sense to me only when I began practicing it repeatedly using realistic scenarios. As part of my learning process, I practiced narrative writing using simulated (dummy) Individual Case Safety Report (ICSR) examples . These cases do not involve real patients or real safety data, but they closely resemble the types of cases handled during routine pharmacovigilance work. I compiled all my practice cases in this post so that I can revisit, revise, and deepen my understanding of narrative writing over time. It would also be helpful for other PV learners who want to understand narrative writing through practical examples collected in one place. 🔗 **Re...

Pharmacovigilance Narrative Writing: Guidelines and Standard Structure Introduction to Narrative Writing in Pharmacovigilance Narrative writing is considered one of the most important foundational skills in pharmacovigilance (PV). For freshers entering the drug safety domain, learning how to write a clear, accurate, and well-structured narrative is essential. Narrative writing plays a direct role in the day-to-day handling of safety cases and forms a critical part of regulatory submissions submitted to global health authorities. Regulatory authorities do not rely only on coded data. They carefully review case narratives to understand what happened to the patient, when it happened, and how the event is related to the drug. This post explains narrative writing in pharmacovigilance from a fresher’s perspective, aligned with official guidelines and real-world PV practice.

Signal Detection in Pharmacovigilance: Concepts, Methods, and  Examples Introduction to Signal Detection in Pharmacovigilance Signal detection is one of the most critical activities in pharmacovigilance. It helps identify early warning signs of potential safety issues associated with medicines. Many serious drug risks are first identified through signal detection after a product is marketed. This post explains signal detection in simple terms, using official definitions and practical examples to provide a clear understanding of how safety signals are identified and evaluated in pharmacovigilance.

Learning ICSR Processing in Pharmacovigilance: Practical Case Scenarios for Beginners Last Updated: January 20 26 Disclaimer ✻This content has been created strictly for educational and self-learning purposes . ✻ As a Pharmacovigilance fresher , I practiced these simulated (dummy) ICSR case scenarios to strengthen my understanding of ICSR processing concepts. ✻ All drugs, case scenarios, timelines, and outcomes mentioned are completely fictional and do not represent real patients, real safety reports, or any confidential company data. ✻ This content is not intended to replace official regulatory guidance. Introduction Individual Case Safety Reports (ICSRs) are a core component of Pharmacovigilance and drug safety activities . While regulatory guidelines explain the theory, developing practical understanding requires hands-on case-based learning . To understand the complete workflow of ICSR processing, read our guide on ICSR Processing in Pharmacovigilance: Step-by-Step Workflow. As ...

Country-Specific Pharmacovigilance Regulatory Guidelines: FDA vs EMA Drug Safety Framework Introduction: Understanding Country-Specific Pharmacovigilance Requirements In previous posts, we explored the global pharmacovigilance framework through ICH guidelines. To understand the global pharmacovigilance framework, read our article on Pharmacovigilance (PV) Guidelines , as well as the scientific contributions of CIOMS and the public-health-focused role of the World Health Organization (WHO). These organizations help harmonize pharmacovigilance concepts across regions. However, in real-world pharmacovigilance practice, compliance is ultimately determined by country-specific regulatory authorities. Each region applies global principles through its own legally binding pharmacovigilance regulations. Understanding these country-specific requirements is essential for pharmacovigilance professionals working in global drug safety operations. Why Country-Specific Pharmacovigilance Guidelines Ma...

CIOMS and WHO in Pharmacovigilance: Roles, Working Groups and the Global Drug Safety Framework In our previous post, we discussed the role of the International Council for Harmonization (ICH) in establishing harmonized regulatory guidelines for pharmacovigilance. However, global drug safety does not rely solely on ICH. Two key international organizations also play a major role in shaping pharmacovigilance concepts and practices: the Council for International Organizations of Medical Sciences (CIOMS) and the World Health Organization (WHO). While ICH focuses mainly on regulatory harmonization, CIOMS and WHO contribute to the scientific, ethical, and public health foundations of pharmacovigilance. Their guidance supports consistent drug safety monitoring across countries, healthcare systems, and patient populations. Understanding the roles of CIOMS and WHO is essential for professionals in pharmacovigilance for several reasons: - Their recommendations influence global safety practices. -...

Pharmacovigilance (PV) Guidelines Explained: ICH E2A–E2F and Global Drug Safety Framework Pharmacovigilance (PV) guidelines are official regulatory standards that define how the safety of medicines should be monitored, evaluated, and reported throughout their lifecycle—from clinical development to post-marketing use. To understand key pharmacovigilance concepts used in these guidelines, read our article on Key Terminologies in Pharmacovigilance Explained . These guidelines ensure that adverse drug reactions are detected early, safety information is shared globally, and appropriate regulatory actions are taken to protect patients and public health.

Medical Coding in Pharmacovigilance (PV): MedDRA Hierarchy and Coding Practice Cases Introduction Medical coding in pharmacovigilance involves converting medical information reported in safety cases into standardized terminology. This ensures consistency in adverse event reporting, facilitates signal detection, and supports regulatory authorities in evaluating the safety of medicinal products. Coded safety data is also used in aggregate safety reports such as PSUR and PBRER. Learn more in our article on Aggregate Safety Reporting in Pharmacovigilance . Medical coding is performed as part of Individual Case Safety Report (ICSR) processing. Learn more about the full workflow in our article on ICSR Processing in Pharmacovigilance: Step-by-Step Workflow. Today, adverse events in pharmacovigilance are coded globally using the Medical Dictionary for Regulatory Activities (MedDRA). This article explains the MedDRA hierarchy, coding rules, and provides practical case examples commonly enc...